MBI Business Summary

Maxigen Biotech Inc. (MBI) is a specialized biotechnology firm focused on the research, development, and commercialization of collagen and hyaluronic acid-based medical devices and skincare solutions. The company generates revenue through a diversified mix of proprietary brand sales and high-value OEM/ODM manufacturing services. Its primary business segments include Orthopedics (viscosupplements), Dentistry (bone repair materials), Aesthetic Medicine (injectable fillers), and Advanced Wound Care (collagen matrices). MBI utilizes proprietary extraction and cross-linking technologies to produce medical-grade biomaterials that meet stringent international standards, including US FDA and CE certifications. Within the competitive landscape, MBI faces direct competition from regional peers such as Sunmax Biotechnology, SciVision Biotech, and United Orthopedic Corporation. MBI maintains a superior market position by leveraging its vertically integrated production capabilities and its strategic integration into a global distribution network, allowing it to capture significant market share in the regenerative medicine sector across Asia and North America. Founded in 1998 by Dr. Chang Chi-Hsiung, MBI is currently led by Chairman Lin Yung-Hsiang (Vincent Lin), who also serves as the Chairman of TCI Co., Ltd. (8436.TW). Lin’s leadership marks a pivotal era for MBI, focusing on digital transformation and global supply chain integration following TCI’s acquisition of a controlling stake in 2021. The executive management team includes General Manager Chen Chun-Hung, who brings extensive experience in biopharmaceutical operations and strategic R&D management. The company’s board is heavily influenced by its parent organization, TCI Group, which provides MBI with significant capital resources and access to a vast international client base. This institutional backing, combined with a leadership team experienced in high-growth biotech scaling, ensures MBI remains a dominant force in the medical-grade collagen and hyaluronic acid markets.